medigraphic.com
ISSN 0326-3428 (Impreso)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2024, Número 3

<< Anterior Siguiente >>

Rev Nefrol Dial Traspl 2024; 44 (3)


Protección cardiovascular y renal y balance de potasio - Un desafío con nuevos participantes

Heguilén R, Martínez SJ, Bernasconi AR, Pérez TP

Idioma: Español
Referencias bibliográficas: 59
Paginas: 156-165
Archivo PDF: 485.33 Kb.


FRAGMENTO

La prolongación de la esperanza de vida, fenómeno crecientemente constante en las últimas décadas, ha traído consigo un aumento en la prevalencia de condiciones que requieren de atención e intervención terapéutica. Es así que, aunque la mortalidad por enfermedad cardiovascular (ECV) ajustada por grupo etario y género ha mostrado una tendencia decreciente, especialmente en países desarrollados, éstas continúan siendo la principal causa de muerte; en especial la cardiopatía isquémica y la enfermedad cerebrovascular (EC).
La enfermedad renal crónica (ERC), que se asocia invariablemente con ellas, tanto en la causa como en los efectos, se ha transformado progresivamente en una epidemia global en los últimos 40-50 años. Estadísticas recientes revelan que su prevalencia es de alrededor de 14% en Estados Unidos y entre el 5 y 15% mundialmente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Villar Álvarez F, Banegas Banegas JR, RodríguezArtalejo F, Del Rey Calero J. Mortalidad cardiovascularen España y sus comunidades autónomas (1975-1992)Med Clin (Barc). 110 (1998):321-7

  2. Lalla MT, Medrano MJ, Sierra MJ, Almazán J..Timetrends, cohort effect and spatial distribution ofcerebrovascular disease mortality in Spain. Eur JEpidemiol.1999;15:331-9

  3. United States Renal Data System: 2015 USRDSAnnual Data Report: Epidemiology of Kidney Diseasein the United States. Bethesda, National Institutes ofHealth. 2015. www.usrds.org/2015/view/Default.asxp

  4. De Nicola L, Zoccali C: Chronic kidney diseaseprevalence in the general population: heterogeneityand concerns. Nephrol Dial Transplant. 2016;31:331–335

  5. Programa de Abordaje Integral de EnfermedadesRenales. Presentación de datos renales SegundaEncuesta Nacional de Nutrición y Salud. DíaMundial del Riñón 2020. 2020. EX-2019-69653829-APN-DD#MSYDS s/Proyecto de Resolución deincorporación del Programa Nacional de AbordajeIntegral de Enfermedades Renales a la Dinaient

  6. Inserra F. Enfermedad renal crónica y sus factoresde riesgo en la Argentina. Nefrología. 2007; 27(2):118-121

  7. Koppen BM, Staton BA. Regulation of potassiumbalance. Renal Physiology. 2018; 7:115-30

  8. Palmer BF. Regulation of Potassium homeostasis. ClinJ Am Soc Nephrol. 2015; 10:1050-60

  9. Palmer BF. Managing hyperkalemia caused byinhibitors of the renin - angiotensin - aldosteronesystem. N Engl J Med; 2004, (351):585-592

  10. Mathialahan, K.A. Maclennan, L.N. Sandle, C.Verbeke, G.I. Sandle. Enhanced large intestinalpotassium permeability in end-stage renal disease. JPathol. 2005; (206):46-51

  11. Nunez, J Bayes-Genis A, Zannad F, et al. Longtermpotassium monitoring and dynamics in heartfailure and risk of mortality. Circulation. 2018(137):1320-1330

  12. ldahl M, Jensen AC, Davidsen L, et al. Associations ofserum potassium levels with mortality in chronic heartfailure patients. Eur Heart J. 2017 (38):2890-2896

  13. Yancy CW, Jessup M, Bozkurt B, y cols. ACC/AHA/HFSA Focused Update on New PharmacologicalTherapy for Heart Failure: an update of the 2013ACCF/AHA Guideline for the Management ofHeart Failure: A Report of the American Collegeof Cardiology /American Heart Association TaskForce on Clinical Practice Guidelines and the HeartFailure Society of America. J Am Coll Cardiol. 2016;68:1476-1488

  14. Ponikowski P, Voors AA, Anker SD y cols. ESCguidelines for the diagnosis and treatment of acuteand chronic heart failure: The Task Force for theDiagnosis and Treatment of Acute and ChronicHeart Failure of the European Society of Cardiology(ESC). Developed with the special contribution ofthe Heart Failure Association (HFA) of the ESC.2016; Eur J Heart Fail. 37

  15. MacIsaac RJ, Jerums G, Ekinci EI. Cardio-renalprotection with empagliflozin. Transl Med. 2016; 4(20): 409. doi: 10.21037/atm.2016.10.36

  16. Collins AJ, Pitt B, Reaven, N, Funk, S, McGaughey,D, Wilson D, et al. Association of Serum Potassiumwith All-Cause Mortality in Patients with and withoutHeart Failure, Chronic Kidney Disease, and/orDiabetes. Am J Nephrol. 2017; 46 (3):213-2211

  17. Goyal A, Spertus JA, Gosch K, y cols. Serumpotassium levels and mortality in acute myocardialinfarction. JAMA.2012;307:157-164]

  18. Pitt B, Rossignol P Serum potassium in patients withchronic heart failure: once we make a U-turn whereshould we go? Eur Heart J. 2017; 38:2897-2899

  19. Hayes J, Kalantar-Zadeh K, Lu JL, Turban S,Anderson JE, Kovesdy CP. Association of hypo- andhyperkalemia with disease progression and mortalityin males with chronic kidney disease: the role of race.Nephron Clin Pract. 2012;120:c8-c16

  20. Kovesdy CP, Appel LJ, Grams ME, y cols. Potassiumhomeostasis in health and disease: a scientific workshopco-sponsored by the National Kidney Foundationand the American Society of Hypertension. J Am SocHypertens.2017;11:783-800

  21. Krogager ML, Torp-Pedersen C, Mortensen RL,Kober L, Gislason G, Sogaard P y cols. Shorttermmortality risk of serum potassium levels inhypertension: a retrospective analysis of nationwideregistry data. Eur Heart J. 2017;38:104-112

  22. Kovesdy CP, Matsushita K, Sang Y, y cols. Serumpotassium and adverse outcomes across the range ofkidney function: a CKD Prognosis Consortium metaanalysis.Eur Heart J. 2018;39:1535-1542

  23. Shiyovich A, Gilutz H, Plakht Y. Potassiumfluctuations are associated with in-hospital mortalityfrom acute myocardial infarction. Soroka AcuteMyocardial Infarction II (SAMI-II) project Angiology.2018;69:709-717

  24. Cohn JN, Kowey PR, Whelton PK, Prisant LM.New guidelines for potassium replacement in clinicalpractice: a contemporary review by the NationalCouncil on Potassium in Clinical Practice. Arch InternMed. 2000;160:2429-2436

  25. Cooper LB, Hammill BG, Peterson ED, y cols.Consistency of laboratory monitoring duringinitiation of mineralocorticoid receptor antagonisttherapy in patients with heart failure. JAMA.2015;(314):1973–537.

  26. Savarese G, Carrero JJ, Pitt B, y cols. Factorsassociated with underuse of mineralocorticoidreceptor antagonists in heart failure with reducedejection fraction: an analysis of 11 215 patients fromthe Swedish Heart Failure Registry. Eur J Heart Fail.2018 (20):1326-1334

  27. Maggioni AP, Anker SD, Dahlstrom U, y cols. Arehospitalized or ambulatory patients with heart failuretreated in accordance with European Society ofCardiology guidelines? Evidence from 12,440 patientsof the ESC Heart Failure Long-Term Registry. Eur JHeart Fail. 2013(15):1173-1184

  28. Mei M, Zhou Z, Zhang Q, Chen Y, Zhao H, Shen B.Dual Blockade of the Renin - Angiotensin System: AStrategy that Should Be Reconsidered in CardiorenalDiseases? Nephron. 2021;145:99–106 https://doi.org/10.1159/000513119

  29. Bermejo S, Oriol García C, Rodrígueza E, BarriosaC, Otero S, Mojalc S, Pascuala J, Soler MJ. Bloqueodel sistema renina-angiotensina-aldosterona enpacientes con enfermedad renal diabética avanzada.Nefrología. 2017;38(2):109-126 DOI: 10.1016/j.nefroe.2017.12.002

  30. Hoogwerf BJ. Renin–Angiotensin System Blockadeand Cardiovascular and Renal Protection. Am JCardiol. 2010;105 (1):S30A-35A doi:https://doi.164 ISSN 0326-3428www.org/10.1016/j.amjcard.2009.10.009

  31. Qiao Y, ShinJung-Im, Chen TK, Inker LA, CoreshJ, Alexander GC, Jackson JW, Chang AR, GramsME. Association Between Renin-Angiotensin SystemBlockade Discontinuation and All-Cause MortalityAmong Persons with Low Estimated GlomerularFiltration Rate. JAMA Intern Med. 2020;180(5):718-726. doi:10.1001/jamainternmed.2020.0193

  32. Einhorn LM, Zhan M, Hsu VD, Walker LD, MoenMF, Seliger SL, Weir MR, Fink JC. The frequency ofhyperkalemia and its significance in chronic kidneydisease. Arch Intern Med. 2009;169(12):1156-62

  33. Kashihara N, Kohsaka S, Kanda E, Okami S,Yajima T. Hyperkalemia in real-world patients undercontinuous medical care in Japan. Kidney InternationalReports. 2019;4(9): 1248–1260. S246802491930213X–doi:10.1016/j.ekir.2019.05.018

  34. Wetmore JB, Yan H, Horne L, Peng Y, GilbertsonDT. Risk of hyperkalemia from renin-angiotensinaldosteronesystem inhibitors and factors associatedwith treatment discontinuities in a real-worldpopulation. Nephrol Dial Transplant. (2019)36:826–39. doi: 10.1093/ndt/gfz263].

  35. Kalantar-Zadeh K, Brown A, Chen, JLT, Kamgar M,Lau,WL, Moradi H, Rhee, CM Streja, and KovesdyCP E. Dietary Restrictions in Dialysis Patients: IsThere Anything Left to Eat? Semin Dial. 2015 Mar-Apr;28(2):159-68.doi:10.1111/sdi.12348

  36. Song Y, Lobene AJ, Wang Y, and Gallant KMH. TheDASH Diet and Cardiometabolic Health and ChronicKidney Disease: A Narrative Review of the Evidence inEast Asian Countries. Nutrients. 2021;13:984. https://doi.org/10.3390/nu13030984

  37. Beto JA, Schury KA, and Bansal BK. Strategiesto promote adherence to nutritional advice inpatients with chronic kidney disease: a narrativereview and commentary lInt. J Nephrol RenovascDis. 2016;9:21-33

  38. Colman S, Bross R, Benner D, Chow J, BragliaA,Arzaghi J, Dennis J, Martinez L, Baldo DB, AgarwalV, Trundnowski T, Zitterkoph J, Martinez B, KhawarOS, Kamyar KZ. The Nutritional and InflammatoryEvaluation in Dialysis patients (NIED) study:overview of the NIED study and the role of dietitians.J Ren Nutr. 2005 Apr;15(2):231-43. doi: 10.1053/j.jrn.2005.01.003

  39. Palmer Biff. Potassium Binders for Hyperkalemia inChronic Kidney Disease Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, andHemodialysis. Mayo Clin Proc. 2020; 95(2):339-354https://doi.org/10.1016/j.mayocp.2019.05.019.

  40. Bushinsky DA, Spiegel DM, Gross C, Benton WW,Fogli J, Hill Gallant KM, Du Mond Ch, Block GA,Weir MR, Pitt B. Effect of Patiromer on Urinary IonExcretion in Healthy Adults. Clin J Am Soc Nephrol.2016;11:1769-1776. doi: 10.2215/CJN.01170216.

  41. Pitt B, Anker SD, Bushinsky DA, Kitzman DW,Zannad F, Huang I-Zu, on behalf of the PEARLHFInvestigators. Evaluation of the efficacy andsafety of RLY5016, a polymeric potassium binder,in a double-blind, placebo-controlled study inpatients with chronic heart failure (the PEARLHF)trial. European Heart Journal. 2011;32;820-828doi:10.1093/eurheartj/ehq 502.

  42. Weir MR, Mayo MR, Garza D, Arthur SA, BermanL, Bushinsky D, et al. Effectiveness of patiromer inthe treatment of hyperkalemia in chronic kidneydisease patients with hypertension on diuretics.J Hypertens. 2017;35(1):S57-63. doi: 10.1097/HJH.0000000000001278]

  43. Weir MR, Bakris GL, Gross C, Mayo, MR, GarzaD, Stasiv Y, et al. Treatment with patiromer decreasesaldosterone in patients with chronic kidney disease andhyperkalemia on renin-angiotensin system inhibitors.Kidney Int. 2016; 90:696-704. doi: 10.1016/j.kint.2016.04. 019.41

  44. 44) Weir, MR, Bakris GL, Bushinsky DA, Mayo MR,Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, BermanL, Pitt B, for the OPAL-HK Investigators. Patiromerin Patients with Kidney Disease and HyperkalemiaReceiving RAAS Inhibitors. N Engl J Med. 2015 Jan15;372(3):211-21 doi: 10.1056/NEJMoa1410853

  45. Rossignol P, Williams B, Mayo MR, Warren S,Arthur S, l Ackourey G, White WB, Agarwal R.Patiromer versus placebo to enable spironolactone usein patients with resistant hypertension and chronickidney disease (AMBER): results in the pre-specifiedsubgroup with heart failure. European J of Heart Fail.(2020) 22:1462–1471 doi:10.1002/ejhf.1860.

  46. Butler J, Anker SD, Siddiqi TJ, Coats AJS, DorigottiF, Filippatos G, Friede T, Göhring UM, KosiborodMN, Lund LH, Metra M, Quinn CM, Piña IL, PintoFJ, Rossignol P, Szecsödy P, Van Der Meer P, Weir M,Pitt B. Patiromer for the management of hyperkalemiain patients receiving renin–angiotensin–aldosteronesystem inhibitors for heart failure: design and rationaleof the diamond trial. European J of Heart Fail. 2022;(24):230–238 doi:10.1002/ejhf.2386.

  47. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY,Spinowitz B, Packham D, Roger SD, Yang A, Lerma E,Singh B. Effect of Sodium Zirconium Cyclosilicate onPotassium Lowering for 28 Days Among Outpatientswith Hyperkalemia the HARMONIZE RandomizedClinical Trial. JAMA. 2014;312(21):2223-2233.doi:10.1001/jama.2014.15688.

  48. Roger D, Spinowitzb BS, Lermac EV, Singhd B,Packhamf WK, Al-Shurbajig A, Kosiborodh M.Efficacy and Safety of Sodium Zirconium Cyclosilicatefor Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE. Am J Nephrol.2019; 50(6):473–480 DOI: 10.1159/000504078.

  49. Wesson D. Sodium zirconium cyclosilicate forhyperkalemia: a collateral acid–base benefit? NephrolDial Transplant. (2020) 1–4 doi: 10.1093/ndt/gfaa241

  50. Roger SD, Spinowitz BS, Lerma EV, Fishbane S,Ash SR, Martins JG, Moreno Quinn C, PackhaDK. Sodium zirconium cyclosilicate increases serumbicarbonate concentrations among patients withhyperkalaemia: exploratory analyses from threerandomized, multi-dose, placebo-controlled trials.Nephrol Dial Transplant. (2020) 1–13 doi: 10.1093/ndt/gfaa15

  51. Spinowitz BS, Fishbane S, Pergola PE, Roger SD,Lerma EV, Butler J, von Haehling S, Adler SH, ZhaoJ, Singh B, Lavin PT, McCullough PA, Kosiborod M,and Packham DK, on behalf of the ZS-005 StudyInvestigators. Sodium Zirconium Cyclosilicate amongIndividuals with Hyperkalemia. A 12-Month Phase3 Study. CJASN. 14:798-809, 2019. doi: https://doi.org/10.2215/CJN.12651018

  52. Peacock WF, Rafique Z, Vishnevskiy J, MichelsonE, Vishneva E, Zvereva T, Nahra R, Li D, Miller J.Emergency Potassium Normalization TreatmentIncluding Sodium Zirconium Cyclosilicate: A PhaseII, Randomized, Double-Blind, Placebo-ControlledStudy (ENERGIZE) Acad Emerg Med. 2020 Jun;27(6):475–486. doi: 10.1111/ACEM.13954].

  53. Fishbane S, Ford M, Fukagawa M, McCafferty K,Rastogi A, Spinowitz B, Staroselskiy K, VishnevskiyK, Lisovskaja V, Al-Shurbaji A, Guzman N,Bhandari S. A Phase 3b, Randomized, Double-Blind,Placebo Controlled Study of Sodium ZirconiumCyclosilicate for Reducing the Incidence of PredialysisHyperkalemia. J Am Soc Nephrol. 2019;30 (9):1723-1733. doi: 10.1681/ASN.2019050450

  54. Nagard M, Kramer WG, Boulton DW- Evaluationof potential drug interactions with sodium zirconiumcyclosilicate: a single-center, open-label, one sequencecrossover study in healthy adults. Clinical KidneyJournal. 2021; 14 (7):1808–1816 doi: 10.1093/ckj/sfaa222.

  55. Lerman EV, Wilson DJ. Finerenone: amineralocorticoid receptor antagonist for thetreatment of chronic kidney disease associated withtype 2 diabetes. Expert Review of Clinical Pharmacology.2022;15 (5):501-513]

  56. Agarwal R, Joseph A, Anker SD, Filippatos G,Rossin P, Ruilope LM, Pitt B, Kolkhof P, Scott C,Lawatscheck R, Wilson DJ, Bakris G, FIDELIO-DKDinvestigators. J Am Soc Nephrol. 2022; 33(1):225-237.doi: 10.1681/ASN.2021070942

  57. Butler J, Zannad F, Fitchett D, Zinman B,Koitka-Weber A, von Eynatten, Zwiener I, GeorgeJ, Brueckmann M, Cheung AK, Wanner C.Empagliflozin Improves Kidney Outcomes in Patientswith or Without Heart Failure. Circulation. https://doi.org/10.1161/circulationhearthfailure.118.0058752019;12 (6)

  58. MacIsaac RJ, Jerums G, Ekinci EI. Cardiorenalprotection with empagliflozin. Transl Med.2016;4(20):409. doi: 10.21037/atm.2016.10.36

  59. Neuen BL; Oshima M, Agarwal R, Arnott C, CherneyDZ, Langkilde AM, Mahaffey KW, McGuire DK, NealB, Perkovic V, Pong A, Sabatine MS, Raz I, ToyamaT, Wanner C, Wheeler DC, Wiviott SD, ZinmanB, Herspink HJL. Sodium-Glucose Cotransporter 2Inhibitors and Risk of Hyperkalemia in People withType 2 Diabetes: A Meta-Analysis of IndividualParticipant Data from Randomized Controlled Trial.Circulation HF. 2022;145 (19) https://doi.org/10.1161/circulationaha 121.057736




2020     |     www.medigraphic.com